Using our revolutionary KnotBody® technology, we are creating first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases.
It affects ~1.5 billion people worldwide and ~64% of patients on the current pain medications are inadequately treated.
More than 300 million people worldwide suffer from autoimmune disorders.
Cardiovascular disease is the leading cause of death globally.
Ion channel and GPCR disfunction are implicated in a wide range of debilitating diseases and current treatments based on small molecule drugs suffer from poor efficacy and side effects.
Compared to small molecules, engineered antibodies offer vastly superior selectivity and are well proven therapeutically, representing 7/10 of top-selling drugs.
Despite these obvious advantages, antibody discovery against ion channel and GPCRs has been challenging.
By fusing naturally occurring cysteine-rich miniproteins (‘Knottins’) into antibody binding loops, our patented KnotBody® technology combines the power of millions of years of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques, addressing key challenges in ion channel and GPCR drug discovery.
Multifunctionality
Potency and Selectivity
Half-life & Manufacturability
Multifunctionality
Potency & Selectivity
Half-life & manufacturability
We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets.
Arndt Schottelius, MD, PhD
CEO
John McCafferty, PhD
Co-founder and CTO
Aneesh Karatt-Vellatt, PhD
Co-founder and CSO
Eva-Lotta Allan
Independent Chair
Thomas Weaver, PhD
Non-Executive Director
CEO Petmedix
Dr Tim Funnell
Partner
Monograph Capital
Lucy Edwardes Jones
Investor
BGF
Dr Sohaib Mir
Senior Investment Principal
LifeArc Ventures
